Physician profile
Steven Back
NPI 1346653946
$6,381.69
in general payments reported to CMS, 2019-2025
27 companies · $1,183 in 2025
The $1,183 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $256 · 2021: $801 · 2022: $1,204 · 2023: $1,268 · 2024: $931 · 2025: $1,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,382.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,234.18 | 2021-2024 | Symplicity G3, Onyx Frontier |
| Biotronik INC. | $1,157.27 | 2023-2025 | Biomonitor, Amvia Edge |
| Cardiovascular Systems INC. | $617.78 | 2019-2022 | |
| Boston Scientific Corporation | $421.45 | 2023-2024 | Watchman Flx, Watchman Access System, Wolverine Coronary Cutting Balloon |
| Novartis Pharmaceuticals Corporation | $375.06 | 2019-2025 | |
| Abiomed | $320.85 | 2023-2025 | Impella |
| Asahi Intecc USA, INC. | $317.16 | 2020-2021 | |
| Medtronic Vascular, INC. | $288.46 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $232.45 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $212.25 | 2019-2025 | Brilinta, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $202.69 | 2019-2023 | Camzyos |
| Pfizer INC. | $187.34 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.55 | 2019-2025 | Jardiance |
| Zoll Respicardia, INC. | $148.42 | 2023 | Remede System |
| Amgen INC. | $133.85 | 2023-2025 | Repatha, Repatha |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $88.87 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Scientific Affairs, LLC | $78.80 | 2024 | Xarelto |
| Bardy Diagnostics, INC. | $50.00 | 2022 | |
| Lilly USA, LLC | $20.67 | 2025 | Zepbound |
| Inspire Medical Systems, INC. | $20.59 | 2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $19.83 | 2024 | Evkeeza |
| C. R. Bard, INC. & Subsidiaries | $19.39 | 2025 | Lutonix Drug Coated Balloon |
| Scpharmaceuticals INC. | $18.48 | 2024 | |
| Janssen Pharmaceuticals, INC | $17.50 | 2024 | Xarelto |
| Terumo Medical Corporation | $16.60 | 2020 | |
| Esperion Therapeutics, INC. | $13.29 | 2024 | Nexletol |
| Cardiva Medical, INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Back listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.